Ankur Jindal

4.9k total citations · 1 hit paper
121 papers, 2.0k citations indexed

About

Ankur Jindal is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Ankur Jindal has authored 121 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Hepatology, 55 papers in Epidemiology and 25 papers in Surgery. Recurrent topics in Ankur Jindal's work include Liver Disease Diagnosis and Treatment (49 papers), Liver Disease and Transplantation (46 papers) and Hepatitis C virus research (15 papers). Ankur Jindal is often cited by papers focused on Liver Disease Diagnosis and Treatment (49 papers), Liver Disease and Transplantation (46 papers) and Hepatitis C virus research (15 papers). Ankur Jindal collaborates with scholars based in India, United States and Malaysia. Ankur Jindal's co-authors include Shiv Kumar Sarin, Radhakrishnan Mahesh, Manoj Kumar, Guresh Kumar, Rakhi Maiwall, Saggere Muralikrishna Shasthry, Shvetank Bhatt, Rakesh Kumar Jagdish, Ankit Bhardwaj and Ashok Choudhary and has published in prestigious journals such as SHILAP Revista de lepidopterología, Hepatology and Gut.

In The Last Decade

Ankur Jindal

112 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis

2022 94 citations Càndid Villanueva, Ferràn Torres et al. Journal of Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ankur Jindal India	22	1.0k	942	453	355	188	121	2.0k
Sergio Neri Italy	25	666 0.7×	582 0.6×	405 0.9×	273 0.8×	118 0.6×	110	2.2k
Luisa Vonghia Belgium	24	1.6k 1.6×	569 0.6×	306 0.7×	373 1.1×	459 2.4×	58	2.6k
E. Buzzigoli Italy	19	1.4k 1.4×	233 0.2×	416 0.9×	754 2.1×	175 0.9×	31	2.8k
Shukun Yao China	23	359 0.4×	112 0.1×	246 0.5×	576 1.6×	78 0.4×	96	1.5k
C. Di Padova Italy	19	875 0.9×	238 0.3×	280 0.6×	284 0.8×	943 5.0×	50	2.2k
Hauke Rensing Germany	25	239 0.2×	148 0.2×	306 0.7×	561 1.6×	147 0.8×	60	1.5k
Roberto Leo Italy	17	220 0.2×	181 0.2×	213 0.5×	122 0.3×	55 0.3×	24	1.3k
M Frezza Italy	14	1.0k 1.0×	500 0.5×	192 0.4×	155 0.4×	765 4.1×	33	1.9k
Nikolaos Perakakis United States	24	910 0.9×	123 0.1×	418 0.9×	724 2.0×	84 0.4×	60	2.9k
Joël Lavoie Canada	21	244 0.2×	351 0.4×	215 0.5×	238 0.7×	71 0.4×	27	1.5k

Countries citing papers authored by Ankur Jindal

Since Specialization

Citations

This map shows the geographic impact of Ankur Jindal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ankur Jindal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ankur Jindal more than expected).

Fields of papers citing papers by Ankur Jindal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ankur Jindal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ankur Jindal. The network helps show where Ankur Jindal may publish in the future.

Co-authorship network of co-authors of Ankur Jindal

This figure shows the co-authorship network connecting the top 25 collaborators of Ankur Jindal. A scholar is included among the top collaborators of Ankur Jindal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ankur Jindal. Ankur Jindal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jindal, Ankur, Manoj Kumar, Vinod Arora, et al.. (2025). Efficacy and Safety of Carvedilol in Cirrhosis Patients With New-Onset Uncomplicated Ascites Without High-Risk Esophageal Varices (CARVE-AS Trial). The American Journal of Gastroenterology.

Kulkarni, Anand V., Rakhi Maiwall, Vinod Arora, et al.. (2025). Addition of midodrine to albumin reduces the incidence of complications of large-volume paracentesis: an RCT comparing midodrine, terlipressin, and albumin. Hepatology International. 19(5). 1231–1241. 1 indexed citations

Shalimar, S., et al.. (2024). Nurse-led virtual clinic for liver cirrhosis: impact on quality of life and health outcomes – a mixed methods research proposal. Gastrointestinal Nursing. 22(Sup6). S28–S36.

Choudhury, Ashok, Saggere Muralikrishna Shasthry, Ankur Jindal, et al.. (2024). Outcomes with radiotherapy in multimodality treatment for hepatocellular carcinoma with portal vein tumour thrombosis. BJR|Open. 7(1). tzaf002–tzaf002. 3 indexed citations

Mukund, Amar, et al.. (2023). Percutaneous ablative therapies for hepatocellular carcinoma in the caudate lobe of the liver: efficacy and outcome. British Journal of Radiology. 96(1148). 20220086–20220086. 3 indexed citations

Kumar, Karan, Ankur Jindal, Ekta Gupta, et al.. (2023). Long Term HBsAg Responses to Peg-Interferon Alpha-2b in HBeAg Negative Chronic Hepatitis B Patients Developing Clinical Relapse after Stopping Long-Term Nucleos(t)ide Analogue Therapy. Journal of Clinical and Experimental Hepatology. 14(1). 101272–101272. 2 indexed citations

Jindal, Ankur, Rakhi Maiwall, Anil K. Sood, et al.. (2023). Tolerance of standard dose albumin infused over 6 hrs for treatment of spontaneous bacterial peritonitis—A randomized controlled trial. Indian Journal of Gastroenterology. 42(4). 505–516.

Mukund, Amar, et al.. (2023). Emergent rescue transjugular intrahepatic portosystemic shunt within 8 h improves survival in patients with refractory variceal bleed. Hepatology International. 17(4). 954–966. 5 indexed citations

Kumar, Manoj, Ankur Jindal, Ashish Kumar Vyas, et al.. (2022). Immune predictors of hepatitis B surface antigen seroconversion in patients with hepatitis B reactivation. Alimentary Pharmacology & Therapeutics. 57(6). 689–708. 6 indexed citations

10.

Villanueva, Càndid, Ferràn Torres, Shiv Kumar Sarin, et al.. (2022). Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. Journal of Hepatology. 77(4). 1014–1025. 94 indexed citations breakdown →

11.

Gupta, Ekta, et al.. (2021). Naturally Occurring Resistance Associated Substitutions in Non-Cirrhotic, Treatment Naive HCV–HIV Co-Infected Patients Does Not Affect the Treatment Response for Anti-HCV Antiviral Therapy. Infection and Drug Resistance. Volume 14. 1381–1387. 1 indexed citations

12.

Jindal, Ankur, Rakesh Kumar Jagdish, & Anupam Kumar. (2021). Hepatic Regeneration in Cirrhosis. Journal of Clinical and Experimental Hepatology. 12(2). 603–616. 6 indexed citations

13.

Philips, Cyriac Abby, Rakhi Maiwall, Manoj Kumar, et al.. (2021). Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis (FRISC study): a randomized controlled trial. Hepatology International. 15(4). 983–994. 51 indexed citations

14.

Koffas, Apostolos, Manoj Kumar, Upkar S. Gill, et al.. (2021). Chronic hepatitis B: the demise of the ‘inactive carrier’ phase. Hepatology International. 15(2). 290–300. 20 indexed citations

15.

Kumar, Manoj, Sachin Kumar, Ankit Bhardwaj, et al.. (2020). Prevalence of and Factors Associated with Sleep-Wake Abnormalities in Patients with Cirrhosis. Journal of Clinical and Experimental Hepatology. 11(4). 453–465. 10 indexed citations

16.

Bhatt, Shvetank, Radhakrishnan Mahesh, Ankur Jindal, & Thangaraj Devadoss. (2016). Neuropharmacological and neurochemical evaluation of N - n - propyl-3-ethoxyquinoxaline-2-carboxamide (6n): a novel serotonergic 5-HT ₃ receptor antagonist for co-morbid antidepressant- and anxiolytic-like potential using traumatic brain injury model in rats. Journal of Basic and Clinical Physiology and Pharmacology. 28(2). 93–100. 8 indexed citations

17.

Bhatt, Shvetank, Radhakrishnan Mahesh, Thangaraj Devadoss, & Ankur Jindal. (2016). Neuropharmacological evaluation of a novel 5-HT ₃ receptor antagonist (4-benzylpiperazin-1-yl)(3-methoxyquinoxalin-2-yl) methanone (6g) on lipopolysaccharide-induced anxiety models in mice. Journal of Basic and Clinical Physiology and Pharmacology. 28(2). 101–106. 15 indexed citations

18.

Philips, Cyriac Abby, Apurva Pande, Saggere Muralikrishna Shasthry, et al.. (2016). Healthy Donor Fecal Microbiota Transplantation in Steroid-Ineligible Severe Alcoholic Hepatitis: A Pilot Study. Clinical Gastroenterology and Hepatology. 15(4). 600–602. 261 indexed citations

19.

Mahesh, Radhakrishnan, et al.. (2015). Piperazine Analogs of Naphthyridine‐3‐carboxamides and Indole‐2‐carboxamides: Novel 5‐HT₃ Receptor Antagonists with Antidepressant‐Like Activity. Archiv der Pharmazie. 348(1). 34–45. 11 indexed citations

20.

Bhatt, Shvetank, Radhakrishnan Mahesh, Ankur Jindal, & Thangaraj Devadoss. (2014). Neuropharmacological effect of novel 5-HT3 receptor antagonist, N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n) on chronic unpredictable mild stress-induced molecular and cellular response: Behavioural and biochemical evidences. Pharmacological Reports. 66(5). 804–810. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact